Why does COVID‐19 pathology have several clinical forms?-Reference-Cited by-同舟云学术

Why does COVID‐19 pathology have several clinical forms?

Published:2020-11-11 Issue:12 Volume:42 Page:2000198
ISSN:0265-9247
Container-title:BioEssays
language:en
Short-container-title:BioEssays

Author:

Aliabadi Fatemeh¹,Ajami Marjan²,Pazoki–Toroudi Hamidreza¹³^ORCID

Affiliation:

1. Physiology Research Center, Department of Medicine Iran University of Medical Sciences Tehran Iran

2. Department of Food and Nutrition Policy and Planning Research, National Nutrition and Food Technology Research Institute Shahid Beheshti University of Medical Sciences Tehran Iran

3. Department of Physiology, Department of Medicine Iran University of Medical Sciences Tehran Iran

Publisher

Wiley

Subject

General Biochemistry, Genetics and Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bies.202000198

Reference93 articles.

1. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

2. Use of triiodothyronine to treat critically ill COVID-19 patients: a new clinical trial

3. Il-1β and prostaglandin E2 attenuate the hypercapnic as well as the hypoxic respiratory response via prostaglandin E receptor type 3 in neonatal mice

4. Major role of adipocyte prostaglandin E2 in lipolysis-induced macrophage recruitment

5. Prostaglandin E2 Induces Hypoxia-inducible Factor-1α Stabilization and Nuclear Localization in a Human Prostate Cancer Cell Line

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting SIRT1 by Scopoletin to Inhibit XBB.1.5 COVID-19 Life Cycle;Current Reviews in Clinical and Experimental Pharmacology;2024-03-01

2. Quercetin may reduce the risk of developing the symptoms of COVID-19;AVICENNA J PHYTOMEDI;2024

3. Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection;Signal Transduction and Targeted Therapy;2023-06-07

4. A Systematic Review on the Safety and Efficacy of COVID-19 Vaccines Approved in Saudi Arabia;Vaccines;2023-01-28

5. Plasma proteomic and metabolomic characterization of COVID-19 survivors 6 months after discharge;Cell Death & Disease;2022-03-14